Effect of imeglimin on metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes - Naruyoshi Gyoutoku; Yukihiro Inoguchi; Junjiro Rikitake; Mutsuyuki Demiya; Mizuki Gobaru; Ayako Nagayama; Shimpei Iwata; Nao Hasuzawa; Hitomi Nakayama; Kenji Ashida; Masatoshi Nomura (PLoS ONE, 2025)